tetano
Editor, Senior Moderator
Glob Health Med
. 2022 Aug 31;4(4):233-236.
doi: 10.35772/ghm.2022.01030.
A novel anticoagulation treatment protocol using unfractionated heparin for coronavirus disease 2019 patients in Japan, 2022
Lubna Sato[SUP] 1 2 [/SUP], Masahiro Ishikane[SUP] 1 [/SUP], Nobumasa Okumura[SUP] 1 [/SUP], Noriko Iwamoto[SUP] 1 [/SUP], Kayoko Hayakawa[SUP] 1 [/SUP], Ken Iseki[SUP] 2 [/SUP], Hisao Hara[SUP] 3 [/SUP], Norio Ohmagari[SUP] 1 [/SUP]
Affiliations
Abstract
Hypercoagulability, which can be induced by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays an important role in the pathogenesis of coronavirus disease 2019 (COVID-19). Although anticoagulation therapy is expected to decrease the incidence of thrombosis and mortality in COVID-19 patients, the optimal use of anticoagulation therapy has not been established, especially using unfractionated heparin (UFH). Herein, we suggest a new anticoagulation treatment protocol for the use of UFH in Japanese COVID-19 patients. This protocol considers the safety regarding UFH usage, to lower major bleeding events, and reflects the latest evidence and the current situation regarding anticoagulation therapy in Japan.
Keywords: SARS-CoV-2; hypercoagulability; thrombosis.
. 2022 Aug 31;4(4):233-236.
doi: 10.35772/ghm.2022.01030.
A novel anticoagulation treatment protocol using unfractionated heparin for coronavirus disease 2019 patients in Japan, 2022
Lubna Sato[SUP] 1 2 [/SUP], Masahiro Ishikane[SUP] 1 [/SUP], Nobumasa Okumura[SUP] 1 [/SUP], Noriko Iwamoto[SUP] 1 [/SUP], Kayoko Hayakawa[SUP] 1 [/SUP], Ken Iseki[SUP] 2 [/SUP], Hisao Hara[SUP] 3 [/SUP], Norio Ohmagari[SUP] 1 [/SUP]
Affiliations
- PMID: 36119785
- PMCID: PMC9420327
- DOI: 10.35772/ghm.2022.01030
Abstract
Hypercoagulability, which can be induced by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays an important role in the pathogenesis of coronavirus disease 2019 (COVID-19). Although anticoagulation therapy is expected to decrease the incidence of thrombosis and mortality in COVID-19 patients, the optimal use of anticoagulation therapy has not been established, especially using unfractionated heparin (UFH). Herein, we suggest a new anticoagulation treatment protocol for the use of UFH in Japanese COVID-19 patients. This protocol considers the safety regarding UFH usage, to lower major bleeding events, and reflects the latest evidence and the current situation regarding anticoagulation therapy in Japan.
Keywords: SARS-CoV-2; hypercoagulability; thrombosis.